Inozyme Pharma — Technical Presentation (May 2024)
19 slides from Inozyme Pharma's technical presentation, May 26, 2024
Slide 1: Impact of INZ-701 on Bone and Mineral Metabolism Biomarkers and Clinical Outcomes in Adults with ENPP1 Deficiency
Impact of INZ-701 on Bone and Mineral Metabolism Biomarkers and Clinical Outcomes in Adults with ENPP1 Deficiency – Results from 48-week Phase 1/2 Open Label Study Yves Sabbagh,1 Robert Wermers,2 Rainard Fuhr,3 Dirk Schnabel,4 Alix Bensacon,5 Deborah Wenkert6, Kurt Gunter1 1Inozyme Pharma, Boston, U
Slide 2: Disclosures
Disclosures This study was funded by Inozyme Pharma. • YS and KG are employees of and stockholders in Inozyme Pharma. • DW is a former employee of Inozyme Pharma. • RF is an employee of Parexel, the sponsor’s CRO for study conduct. • RW, DS and AB have nothing to disclose.
Slide 3: ENPP1 is a key component of the pyrophosphate-adenosine pathway
ENPP1 is a key component of the pyrophosphate-adenosine pathway1-3 1 ABCC6 and ANK 2 3 Pyrophosphate (PPi) regulates CD73 metabolizes transport ATP from ENPP1 metabolizes AMP into Pi and skeletal mineralization1 intracellular to ATP into PPi and AMP adenosine extracellular space Adenosine inhibits v
Slide 4: Low PPi and low adenosine due to ENPP1 Deficiency lead to ectopic calcification and arterial intimal proliferation
Low PPi and low adenosine due to ENPP1 Deficiency lead to ectopic calcification and arterial intimal proliferation1-3 Low PPi levels lead to soft tissue mineralization1 Low adenosine levels lead to intimal proliferation and artery lumen narrowing1-3 Nonfunctional ENPP1 enzyme ENPP1 gene mutation(s)
Slide 5: The Natural History of ENPP1 Deficiency
The Natural History of ENPP1 Deficiency1-5 INFANCY* CHILDHOOD/ ADOLESCENCE ADULTHOOD Rickets (Xray) Osteomalacia (Xray) Findings Arterial calcification (CT, US) Hypophosphatemia, inc. FGF23 (labs) Hypophosphatemia, inc FGF23 (labs) Arterial stenosis (CTA, US) Joint/ ligament calcification (X-ray, CT
Slide 6: Adult ENPP1 Deficiency Phase 1/2 trial
Adult ENPP1 Deficiency Phase 1/2 trial A Phase 1/2, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 followed by an open-label long-term extension period in adults with ENPP1 Deficiency Study Population: Primary Goals S
Slide 7: Purpose
Purpose: To describe the safety and exploratory efficacy of INZ-701 in adults with ENPP1 Deficiency through the end of the phase 2 study period (week 48). 7
Slide 8: Results: Baseline Demographics
Results: Baseline Demographics Cohort 1 Cohort 2 Cohort 3 Cohort 4 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg biweekly biweekly biweekly weekly (n=3) (n=3) (n=3) (n=4) AGE (YEARS) Median 31 43 25 29 Range 23-40 30-58 22-29 20-58 GENDER Male (n=5) 0 1 2 2 Female (n=8) 3 2 1 2 RACE White (n=9) 3 3 2 1 As
Slide 9: Results: Medical History
Results: Medical History Cohort 1 Cohort 2 Cohort 3 Cohort 4 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg Total MEDICAL CONDITION biweekly biweekly biweekly weekly (n=13) (n=3) (n=3) (n=3) (n=4) Rickets/osteomalacia 3 2 3 4 12 Cardiovascular disease 2 3 2 3 10 Arterial calcification/stenosis/surgery 2 3
Slide 10: INZ-701 exhibited a favorable safety profile across dosing cohorts
INZ-701 exhibited a favorable safety profile across dosing cohorts INZ-701 dose cohort – No. of patients with at least one event 0.2 mg/kg 0.6 mg/kg 1.8 mg/kg 1.2 mg/kg Total patients Event biweekly biweekly biweekly weekly (n=13) n=3 n=3 n=3 n=4 Adverse event (AE) 3 3 2 3 11 Adverse event related t
Slide 11: Favorable immunogenicity profile observed
Favorable immunogenicity profile observed Low, non-neutralizing anti-drug antibodies (ADAs) were detected; Transient in at least 3 of 11 patients Anti-Drug Antibody (ADA) Status and Titers Weeks 2 3 4 5 12 24 36 48 60 72 84 96 Highest ADA titer Cohort 1 1 40 40 80 40 160 40 <40 160 2 80 40 80 3 80 W
Slide 12: Plasma PPi by Dosing Group
Results: Plasma PPi by Dosing Group Phase 1 Phase 2 3000 (0.2mg/kg) 2500 Cohort 1 Plasma PPi (nM) 2000 1500 1000 • Rapid increase observed after the 500 1st dose 0 0 10 20 30 40 100 200 300 400 500 600 700 3000 Days • PPi levels reached the healthy (0.6mg/kg) volunteer range after the 1st dose Plasm
Slide 13: Pooled Plasma PPi, Serum FGF-23, and Serum Pi
Results: Pooled Plasma PPi, Serum FGF-23, and Serum Pi Pooled Cohorts 1-3: Baseline vs mean Week 2-48 PPi, FGF-23, and Pi levels (±SEM) 3000 Plasma PPi 150 2.6 Serum Pi Serum FGF-23 Serum Pi (mg/dL) FGF-23 (pg/mL) 2.4 Plasma PPi (nM) 2000 100 2.2 Baseline 50 2.0 1000 1.8 0 1.6 0 0 10 20 30 40 50 0 1
Slide 14: Bone Mineral Biomarkers by Dosing Group
Results: Bone Mineral Biomarkers by Dosing Group Cohort 1 Cohort 2 Cohort 3 (0.2mg/kg, 2x/week) (0.6mg/kg, 2x/week) (1.8mg/kg, 2x/week) 75 75 75 (% change from baseline) (% change from baseline) (% change from baseline) Bone-specific alkaline phosphatase (BSAP): Key 50 50 50 enzyme involved in miner
Slide 15: 6-Minute Walk Test (6-MWT) by Dosing Group and by Baseline 6-MWT
Results: 6-Minute Walk Test (6-MWT) by Dosing Group and by Baseline 6-MWT Greater improvement observed in patients with poor baseline 6-MWT 4 Cohort 1 Patients with <70% predicted of healthy 6-MWT at baseline (n=5) 6-MWT 6-MWT % Predicted Normal Serum Pi (mg/dL) Cohort 2 100 550 6-MWT Absolute Dista
Slide 16: PROMIS Scale (PRO) by Dosing Group
Results: PROMIS Scale (PRO) by Dosing Group Improvements seen at all dose levels Pain Intensity Pain Interference Fatigue Responders Responders Responders Cohort Cohort Cohort (n) (n) (n) Cohort 1 Cohort 1 Cohort 1 Cohort 2 Cohort 2 Cohort 2 Cohort 3 Cohort 3 Cohort 3 Total Total Total Responder def
Slide 17: Global Impression of Change Scale
Results: Global Impression of Change Scale Cohort 1 (0.2mg/kg) (n=3) Cohort 2 (0.6mg/kg) (n=3) Cohort 3 (1.8mg/kg) (n=3)* 3 3 3 Global Clinician’s Global 2 2 2 Impression Impression 1 1 1 Clinician’s C-GIC C-GIC C-GIC 0 0 0 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 -1 -1 -1 Weeks Weeks Weeks -2 -
Slide 18: Conclusions
Conclusions Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency successfully met all study objectives • Study fully enrolled in all 4 cohorts (n=13) • PK data from cohort 4 support once per week dosing in future clinical studies in ENPP1 Deficiency • Favorable safety profile was maintained o
Slide 19: Acknowledgements
Acknowledgements The authors would like to thank the patients and their families who took part in this clinical study. We acknowledge the contributions of investigators and study coordinators. 19